Please provide your email address to receive an email when new articles are posted on . Treatment with GLP-1RAs resulted in significant mean reductions in ALT by 23.4 U/L at 6 months and by 18.2 U/L ...
Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback